Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
23 mars 2022 16h05 HE
|
Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
Cocrystal Pharma to Participate in Upcoming Investment Conferences
03 mars 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor...
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
06 janv. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP)...
Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant
22 déc. 2021 08h00 HE
|
Cocrystal Pharma, Inc.
Antiviral activity now confirmed against SARS-CoV-2 and all variants of concernincluding Omicron, Delta, Alpha, Beta and Gamma BOTHELL, Wash., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma,...
Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses
08 nov. 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 main protease inhibitors showed potent in vitro...
Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, announces that management will...
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
23 juin 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
17 mai 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
03 mai 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference
03 sept. 2019 08h05 HE
|
Cocrystal Pharma, Inc.
- CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study...